Caprelsa
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
| Name | Caprelsa |
|---|---|
| Active Substance | vandetanib |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ograničeni recept |
| Distribution | Supply through pharmacies (community) |
| ATC Code | L01EX04 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
| Link to the European Medicines Agency's (EMA) product information | download |
| Link to the European Commission's (EC) decisions | download |
| Educational materials for healthcare professionals |
Edukacijski materijal za zdravstvene radnike, verzija 3 |
| Educational materials for patients / caregivers |
Vodič za skrbnike i bolesnike za doziranje i praćenje, verzija 3 Kartica za bolesnike, verzija 3 |
Packaging
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o ograničenju indikacije za lijek Caprelsa (vandetanib) - ažurirano | 02.03.2023 | Genzyme Europe B.V. |
| Pismo zdravstvenim radnicima o sličnosti naziva lijekova Caprelsa (vandetanib) i Caprez (amlodipin) | 21.02.2017 | Sanofi-aventis Croatia d.o.o., AstraZeneca d.o.o., Alkaloid d.o.o. |
